BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The company also reported significant progress toward its internally defined Sustainable Development Goals
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
India plays a critical role in Bristol Myers Squibb’s global strategy
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Subscribe To Our Newsletter & Stay Updated
